Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs

Seminars in Arthritis and Rheumatism

Volumn 39, Issue 6, 2010, Pages 425-441

  Bergman, Gert J D ^a   Hochberg, Marc C ^b   Boers, Maarten ^c   Wintfeld, Neil ^d   Kielhorn, Adrian ^f   Jansen, Jeroen P ^e  

^a MAPI GROUP   (Netherlands)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d International Economic Strategy Manager   (United States)

^e National Project Manager   (Switzerland)

^f Research Director Mapi Values   (United States)

Author keywords

Biologic DMARDs; Mixed treatment comparison; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EMBASE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; JOINT SWELLING; MEDICAL LITERATURE; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES; VISUAL ANALOG SCALE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953122551     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.12.002     Document Type: Article

References (33)

1. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002, 46:328-346. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines.
2. Ledingham J., Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005, 44:157-163.
3. Guide to the methods of technology appraisal 2008, National Institute of Health and Clinical Excellence, National Institutes of Health and Clinical Excellence, United Kingdom, 35.
4. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
5. Song F., Altman D.G., Glenny A.M., Deeks J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br Med J 2003, 326:472.
6. Caldwell D.M., Gibb D.M., Ades A.E. Validity of indirect comparisons in meta-analysis. Lancet 2007, 369:270.
7. Jansen J.P., Crawford B., Bergman G., Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11:956-964.
8. Hochberg M.C., Tracy J.K., Hawkins-Holt M., Flores R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003, 62:ii13-ii16.
9. Nixon R.M., Bansback N., Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med 2007, 26:1237-1254.
10. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis: NICE Technology Appraisal Guidance 130 National Institute for Health and Clinical Excellence, London, United Kingdom: 2007. p. 4-40. TA130, Accessed May 5, 2009. http://www.nice.org.uk/TA130.
11. Bland J.M., Altman D.G. Bayesians and frequentists. BMJ 1998, 317:1151-1160.
12. Kremer J., Fleischmann R.M., Saurigny D., Alecock E., Blanco R. Safety and tolerability of tocilizumab in combination with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX: 1-year results of the LITHE study. Ann Rheum Dis 2009, 68(Suppl. 3):444. [Abstract FRI0262].
13. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
14. Genovese M.C., McKay J.D., Nasonov E.L., Mysler E.F., da Silva N.A., Alecock E., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. Arthritis Rheum 2008, 58:2968-2980.
15. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004, 63:508-516.
16. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleischmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999, 130:478-486.
17. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
18. Combe B., Codreanu C., Fiocco U., Gaubitz M., Geusens P.P., Kvien T.K., et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006, 65:1357-1362.
19. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
20. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
21. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial: ATTRACT Study Group. Lancet 1999, 354:1932-1939.
22. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Rox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253-259.
23. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
24. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086.
25. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
26. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
27. Edwards J.C., Szczepanski L., Szechinski J., Filipowicz-Sosnowska A., Emery P., Close D.R., et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.
28. Emery P., Fleischmann R., Filipowicz-Sosnowska A., Schechtman J., Szczepanski L., Kavanaugh A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
29. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
30. Smolen J.S., Beaulieu A.D., Dikranian A., Fenton I., Fisheleva E., Alecock E., et al. Safety of tocilizumab in patients with rheumatoid arthritis: pooled analysis of five phase 3 clinical trials. Arthritis Rheum 2008, 58(Suppl):S784. [Abstract 1669.].
31. van Vollenhoven R.F., Siri D., Furie R., Krasnow J., Alecock E., Alten R. Long-term safety and tolerability of tocilizumab in patients with rheumatoid arthritis and a mean treatment duration of 2.4 years. Arthritis Rheum 2009, 60(Suppl):S731. [Abstract 1955.].
32. ACTEMRA for intravenous infusion [prescribing information] February 2009, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.
33. RoACTEMRA [summary of product characteristics] [prescribing information] January 2009, Roche Registration Limited, Welwyn Garden City, UK.